within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX22_LoncastuximabTesirine;
model LoncastuximabTesirine 
   extends Pharmacolibrary.Drugs.ATC.L.L01FX22;

  annotation(Documentation(
    info ="<html><body><p>Loncastuximab tesirine is an antibody-drug conjugate (ADC) composed of a CD19-directed monoclonal antibody conjugated to a cytotoxic pyrrolobenzodiazepine dimer. It is approved for use in adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adults with relapsed or refractory diffuse large B-cell lymphoma. Data are based on population PK analysis of clinical trial subjects.</p><h4>References</h4><ol></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end LoncastuximabTesirine;
